Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Thomas Moritz Pausch

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6145-3263; OpenAlex author ID A5033502648. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. ChatGPT vs. surgeons on pancreatic cancer queries: accuracy & empathy evaluated by patients and experts. First author DOI 10.1016/j.hpb.2024.11.012↗
  2. Immunohistochemical FAP Expression Reflects 68Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Duc… Co-author DOI 10.2967/jnumed.123.266393↗
  3. Open irreversible electroporation for isolated local recurrence of pancreatic ductal adenocarcinoma after primary surgery. Co-author DOI 10.1016/j.pan.2021.08.002↗
  4. Survival Benefit of Resection Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastases: A Propensity Score-Matched SEER Database Analysis. Co-author DOI 10.3390/cancers14010057↗
  5. Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes. Co-author DOI 10.1038/s41598-020-62416-x↗
  6. Fifty Years of Surgery for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001634↗
  7. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  8. Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer. Co-author DOI 10.1016/j.surg.2012.05.028↗
  9. Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s10456-011-9207-3↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thilo Hackert · 6 shared papers, 2012–2024 · strength 0.77
  2. Ulrike Heger · 2 shared papers, 2021 · strength 0.27
  3. Susanne Roth · 1 shared paper, 2025 · strength 0.23
  4. Martin Loos · 1 shared paper, 2025 · strength 0.23
  5. Azaz Ahmed · 1 shared paper, 2025 · strength 0.23
  6. Jörg Kaiser · 1 shared paper, 2025 · strength 0.23
  7. Rosa Klotz · 1 shared paper, 2025 · strength 0.23
  8. Christoph W. Michalski · 1 shared paper, 2025 · strength 0.23
  9. Christoph Kahlert · 1 shared paper, 2025 · strength 0.23
  10. Manuel Röhrich · 1 shared paper, 2024 · strength 0.21
  11. Anna-Maria Spektor · 1 shared paper, 2024 · strength 0.21
  12. Markus Wolfgang Büchler · 2 shared papers, 2012–2020 · strength 0.18
  13. Ulla Klaiber · 1 shared paper, 2020 · strength 0.15
  14. André L. Mihaljević · 1 shared paper, 2020 · strength 0.15
  15. Pascal Probst · 1 shared paper, 2021 · strength 0.13
  16. Jishu Wei · 1 shared paper, 2021 · strength 0.13
  17. Yi Miao · 1 shared paper, 2021 · strength 0.13
  18. Xinchun Liu · 1 shared paper, 2021 · strength 0.13
  19. Martin A. Schneider · 1 shared paper, 2020 · strength 0.11
  20. Thomas Schmidt · 1 shared paper, 2020 · strength 0.11
  21. Werner Hartwig · 1 shared paper, 2012 · strength 0.03
  22. Lars Grenacher · 1 shared paper, 2012 · strength 0.03
  23. Jens Werner · 1 shared paper, 2012 · strength 0.03
  24. Dirk Bausch · 1 shared paper, 2011 · strength 0.03
  25. Tobias Keck · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.